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1 | INTRODUC TION
Since	 their	 introduction	 in	 2013,	 second-	generation	 direct-	
acting	 antiviral	 (DAA)	 drugs	 have	 improved	 the	 efficacy,	 safety	
and	tolerability	of	treatment	for	chronic	hepatitis	C	virus	 (HCV)	
infection.	 All-	oral,	 interferon-	free	 DAA	 combination	 regimens	
comprising	 ombitasvir/paritaprevir/ritonavir	+	dasabuvir	 (OBV/
PTV/r+DSV)	±	ribavirin	 (RBV)	 and	 OBV/PTV/r	+	RBV	 were	 ap-
proved	for	use	in	the	United	States	and	Europe	in	2014-	20151–4 
and	are	recommended	for	the	treatment	of	HCV	genotypes	(GT)	
1	 and	 4,	 respectively.5,6	 In	 GT1a-	infected	 patients	 without	 cir-
rhosis,	OBV/PTV/r	+	DSV	+	RBV	is	administered	for	12	weeks,	or	
for	 24	weeks	 in	 patients	 with	 compensated	 cirrhosis.	 In	 GT1b-	
infected	patients	without	cirrhosis	or	with	compensated	cirrho-
sis,	OBV/PTV/r	+	DSV	 is	administered	 for	12	weeks	 (or	8	weeks	
with	 mild	 fibrosis	 [F0-	F2]).2,3	 In	 GT4-	infected	 patients,	 OBV/
PTV/r	+	RBV	is	administered	for	12	weeks	regardless	of	cirrhosis	





more than 50 countries.
Notwithstanding	 the	 success	 of	 DAA	 regimens,	 barriers	 to	
HCV	 treatment	 initiation	 remain,	with	 the	presence	of	 comorbidi-
ties	and	the	potential	risk	for	drug-	drug	interactions	(DDIs)	cited	as	
common	 impediments.5	 Patients	with	 chronic	HCV	 infection	have	
a	high	burden	of	comorbid	medical	and	psychiatric	conditions,13–15 
which	 are	 often	 managed	 with	 multiple	 comedications.16 Among 
patients	 treated	with	 currently	 available	DAA	 drugs	who	 are	 tak-
ing	comedications,	at	 least	30%	are	potentially	at	risk	for	clinically	
significant	 DDIs,17	 although	 these	 risks	 vary	 between	 individual	






or	 have	 additional	 comorbidities)	 and	 less	 adherent	 to	 treatment	
regimens.18	 Furthermore,	 clinical	 trials	 are	 designed	 to	 establish	
efficacy outcomes of investigative drugs and are conducted in con-
trolled settings, with strict eligibility criteria that are intended to 
enroll	well-	defined	trial	populations	with	 limited	comorbidities	or	
comedications to mitigate any unwarranted influence on treatment 
safety	and	efficacy	outcomes.	Therefore,	the	results	from	clinical	
virologic	response	at	post-	treatment	Week	12	(SVR12),	adverse	events	(AEs)	and	co-




(n	=	732;	19%),	GT1b	 (n	=	2619;	69%)	or	GT4	 (n	=	457;	12%).	 In	3546	patients	with	
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the	 safety	 and	 effectiveness	 of	DAA	 regimens	 in	 real-	world	 set-
tings	is	important	to	help	guide	patients	and	healthcare	providers	
in	 clinical	 decision-	making	 as	 well	 as	 to	 help	 inform	 regulatory	
decision-	making.19	 At	 present,	 data	 assessing	 the	 real-	world	 ef-
fectiveness	of	OBV/PTV/r	±	DSV	±	RBV	regimens	in	patients	with	
HCV	are	limited.





2  | MATERIAL S AND METHODS
2.1 | Study design
This	was	 an	 analysis	 of	 data	 pooled	 from	AbbVie-	sponsored,	 pro-
spective,	observational	studies	conducted	at	289	sites	 in	13	coun-
tries:	 Austria	 (NCT02582658),	 Belgium	 (NCT02581163),	 Canada	
(NCT02581189),	Colombia	(NCT02851069),	France	(NCT02618928),	
Germany	 (NCT02615145),	 Greece	 (NCT02725866),	 Hungary	
(NCT02636608),	 Ireland	 (NCT02582671),	 Israel	 (NCT02803138),	
Kuwait	 (NCT02798315),	 Poland	 (NCT02640547)	 and	 Romania	
(NCT02807402).	 In	 some	 countries,	 the	 studies	 are	 still	 ongoing.	








scribed by the investigator or designee from the source documents 
into	the	eCRF.
Each	 study	 was	 conducted	 in	 accordance	 with	 local	 laws	 and	
regulations	 and	 received	 the	 required	 approvals	 from	 the	 respon-
sible	 regulatory	 authorities,	 ethics	 committees	 and/or	 competent	
authorities.
2.2 | Study populations and treatments
Analyses	were	performed	 in	 the	following	populations.	The	safety	
population	included	all	male	or	female	patients	who	were	≥18	years	
of	 age,	 chronically	 infected	with	 HCV	GT1	 or	 GT4	 (or	 with	miss-
ing	GT	 information),	and	who	had	received	≥1	dose	of	study	drug.	
Patients	who	were	treatment-	naïve	or	-	experienced	(previous	treat-









and	 patients	 with	 unknown	 HCV	 GT	 or	 cirrhosis	 status.	 Patients	
with	missing	SVR12	values	were	counted	as	nonresponders	 in	 the	
core	population.
The	 core	 population	 with	 sufficient	 follow-	up	 (CPSFU)	 in-
cluded	patients	 from	 the	core	population	apart	 from	 those	with	a	
documented	virologic	 response	at	 their	 last	on-	treatment	or	post-	
treatment	measurement	but	with	no	HCV	RNA	measurements	more	
than	 70	days	 post-	treatment	 for	 reasons	 not	 related	 to	 safety	 or	
effectiveness,	 or	 patients	with	 no	HCV	RNA	measurements	 post-	
baseline or no treatment end date for reasons not related to safety 
or	effectiveness	(eg	lost	to	follow-	up,	consent	withdrawal).
Patients	 infected	 with	 HCV	 GT1a	 received	 OBV/
PTV/r	+	DSV	±	RBV	 regimens	 for	 planned	 treatment	 durations	 of	
12	or	24	weeks.	Patients	 infected	with	HCV	GT1b	 received	OBV/










dosage	 of	OBV/PTV/r	was	 25	mg/150	mg/100	mg	once	 daily,	 and	
DSV	was	250	mg	twice	daily;	weight-	based	RBV	was	administered	
according	to	local	label.	The	choice	of	treatment	regimen	was	at	the	
discretion	of	 the	healthcare	provider	 and	was	 consistent	with	 the	
recommended	label	or	with	local	clinical	practice.
2.3 | Assessments
SVR12	 was	 defined	 as	 an	 HCV	 RNA	 concentration	<50	IU/mL	 at	
12	weeks	 after	 EOT	 (70-	126	days	 after	 the	 last	 dose).	 HCV	 RNA	
measurements	 were	 considered	<50	IU/mL	 if	 HCV	 RNA	 was	 un-
detectable and the lower limit of detection of the assay was 
≤50	IU/mL;	or	HCV	RNA	was	unquantifiable	and	the	lower	limit	of	
quantification	was	 ≤50	IU/mL	 (ie	HCV	RNA	detectable	 but	 below	
the	limit	of	quantification).
Virologic	breakthrough	was	defined	as	≥1	documented	HCV	RNA	
measurement	<50	IU/mL	 followed	 by	HCV	 RNA	≥50	IU/mL	 during	









treatment	until	 after	 the	 last	DAA	dose,	was	documented	 (includ-
ing	opiate	substitution,	contraceptives/hormonal	replacements	and	
herbal	supplements)	 (see	Supplementary	Materials	 for	 information	
on	comedication	coding).
The	management	profiles	of	commonly	used	comedications	with	










•	 permanently	 discontinued	 before	 or	 during	 DAA	 treatment,	 or	
subsequently	resumed	post-treatment;
•	 comedication	was	permanently	or	temporarily	replaced	or	a	sub-
stitute drug used at the start of or during treatment;



















Demographics	 and	 baseline	 characteristics,	 including	 comorbidi-






more	 than	7	days).	 In	each	case,	2-	sided	95%	confidence	 intervals	
(CI)	for	the	binomial	proportion	were	calculated	using	Wilson's	score	
method.	All	 treatment-	emergent	AEs	and	 laboratory	abnormalities	















pitals	 (33%)	 (Figure	S1A).	Most	principal	 investigators	 at	 each	 site	










criteria,	3808	and	3546	patients	 remained	 in	 the	core	and	CPSFU	
populations,	respectively	(Figure	S2).
3.1 | Baseline demographics and clinical 
characteristics
In	 the	 core	 population,	 2034	 patients	 (53%)	 were	 male,	 3375	
(89%)	were	white,	and	the	median	age	was	57	years	(range	18-	90)	







with	 GT4	 than	 GT1	 (69%	 versus	 31%).	 A	 total	 of	 1319	 patients	
(35%)	had	cirrhosis:	133	GT1a-	infected	patients	(18%);	1074	GT1b-	
infected	patients	 (41%);	112	GT4-	infected	patients	 (25%).	 In	1469	
patients	(39%)	who	had	prior	treatment	experience,	1181	patients	
(81%)	had	 received	pegylated	 interferon	alfa	as	 their	most	 recent	
prior	antiviral	treatment;	a	further	252	patients	(17%)	had	received	
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pegylated	 interferon	 (not	 specified),	 interferon	 alfa	 or	 interferon	
(not	 specified).	 Prior	 DAA	 treatment	 was	 taken	 by	 162	 patients	
(11%).	Regarding	current	DAA	regimens,	most	patients	received	12-	
week	regimens:	654	GT1a-	infected	patients	 (89%)	 received	OBV/
PTV/r	+	DSV	+	RBV;	 1773	 GT1b-	infected	 patients	 (68%)	 received	
OBV/PTV/r	+	DSV	and	737	GT1b-	infected	patients	(28%)	received	
OBV/PTV/r	+	DSV	+	RBV;	 and	 424	 GT4-	infected	 patients	 (93%)	
received	 OBV/PTV/r	+	RBV	 (Table	1).	 Overall,	 89	 GT1b-	infected	
patients	 (3%)	 received	planned	 treatment	 for	8	weeks	with	OBV/
PTV/r	+	DSV	 without	 RBV	 (fibrosis	 scores:	 F0-	F1,	 n	=	69	 [84%];	









The	 overall	 SVR12	 rate	 in	 the	 CPSFU	 (whole	 cohort)	 was	 95.9%	
(n/N	=	3401/3546;	95%	CI	95.2-	96.5).	The	SVR12	rate	was	96.2%	
(n/N	=	3009/3129;	 95%	 CI	 95.4-	96.8)	 in	 GT1-	infected	 patients	
(GT1a:	 92.6%	 [n/N	=	603/651;	 95%	 CI	 90.4-	94.4];	 GT1b:	 97.1%	
[n/N	=	2406/2478;	95%	CI	96.4-	97.7]).	The	SVR12	rate	was	94.0%	
(n/N	=	392/417;	95%	CI	91.3-	95.9)	in	GT4-	infected	patients.	SVR12	































































Data	 are	n	 (%)	unless	 stated	otherwise.	Percentages	 are	based	on	pa-
tients with valid values.
















regimens	 are	 shown	 in	 Figure	 S4.	 In	 patients	 infected	with	 GT1a	
treated	 with	 OBV/PTV/r	+	DSV	+	RBV	 for	 planned	 durations	 of	
12	or	24	weeks,	SVR12	rates	were	93.3%	(n/N	=	544/583;	95%	CI	
91.0-	95.1)	and	82.4%	(n/N	=	28/34;	95%	CI	66.5-	91.7),	respectively.	
In	 patients	 infected	 with	 GT1b	 treated	 with	 OBV/PTV/r	+	DSV	
for	 planned	durations	of	 8	or	12	weeks,	 SVR12	 rates	were	96.3%	
(n/N	=	79/82;	95%	CI	89.8-	98.7)	and	96.7%	(n/N	=	1600/1654;	95%	





In	 the	 CPSFU,	 145	 patients	 (4.1%)	 had	 virologic	 nonresponse	
(Table	2).	 The	 reasons	 for	 nonresponse	 were	 as	 follows:	 39	 pa-
tients	 (1.1%)	had	on-	treatment	virologic	 failure;	39	patients	 (1.1%)	
had	post-	treatment	 virologic	 relapse;	 24	patients	 (<1.0%)	 died;	 30	
patients	 (<1.0%)	 prematurely	 discontinued	 treatment	 with	 no	 on-	
treatment	virologic	failure;	13	patients	(<1.0%)	had	insufficient	viro-
logic	response	for	other	reasons.
In	 patients	with	 prior	 HCV	 treatment	 experience	 (Figure	1B),	
the	 SVR12	 rate	was	96.4%	 (n/N	=	1201/1246;	 95%	CI	 95.2-	97.3)	
in	 GT1-	infected	 patients	 (GT1a:	 91.8%	 [n/N	=	178/194;	 95%	 CI	
87.0-	94.9;	GT1b:	97.2%	[n/N	=	1023/1052;	95%	CI	96.1-	98.1]).	The	
SVR12	rate	was	92.4%	(n/N	=	145/157;	95%	CI	87.1-	95.6)	in	GT4-	
infected	patients.	 In	HCV	 treatment–experienced	patients,	 those	





prematurely	 discontinued	 treatment	 after	 15	days	 because	 of	 an	
AE	and	had	no	post-	baseline	measurements;	and	one	patient	died	















GT4,	 n	=	1)	 discontinued	 treatment	 early	 because	 of	 AEs	with	 no	
HCV	 RNA	 collected	 after	 DAA	 treatment	 (two	 patients	 received	
RBV).




virologic	 failure,	 13	 patients	 (<1.0%)	 had	 insufficient	 virologic	 re-
sponse,	and	13	patients	(<1.0%)	died.
3.3 | Management of comedications




GERD	 (10%;	n	=	394)	 (Table	S3A).	The	 three	most	commonly	used	
drugs	(in	≥2%	of	patients)	were	levothyroxine	(7%;	n	=	257),	acetyl-
salicylic	acid	(6%;	n	=	214)	and	amlodipine	(6%;	n	=	214)	(Table	S3B).	
Based	 on	 information	 available	 at	 https://www.hep-druginterac-
tions.org/,21 none of these commonly used drugs were contraindi-
cated	 for	 use	with	OBV/PTV/r	±	DSV	 and	 seven	medications	 had	
established	 or	 potentially	 clinically	 relevant	 DDIs	 (levothyroxine,	
amlodipine,	 bisoprolol,	 pantoprazole,	 furosemide,	 indapamide	 and	
omeprazole;	Table	S3B).
Comedication	use	was	continued	for	the	entire	duration	of	OBV/




DAA	 treatment	 and	 84	 discontinued	 their	 comedications	 during	
DAA	 treatment	 (<5%	 for	 each).	 Comedications	were	 discontinued	
prior	to	the	 initiation	of	OBV/PTV/r	±	DSV	±	RBV	treatment	and	
subsequently	 resumed	 post-	treatment	 without	 replacement	 in	




3.3.1 | Management profiles for specific 
comedications
The	management	profiles	 for	 specific	 comedications	 that	are	con-
sidered	 to	 have	 a	 high	 DDI	 potential	 are	 shown	 in	 Figure	 S7.	 In	
the	overall	population,	417	patients	 (11%)	 received	drugs	 for	pep-
tic	 	ulcers	and	GERD,	95	patients	 (2%)	 received	antiepilepsy	drugs,	
and	90	patients	 (2%)	 received	antipsychotic	drugs	prior	 to	or	dur-
ing	 OBV/PTV/r	±	DSV	±	RBV	 treatment.	 The	 majority	 of	 patients	
(80%-	93%;	four	patients	had	no	profile	reported)	maintained	these	
comedications	without	change	(ie	no	comedication	discontinuation,	





statin	 therapy	 before	 DAA	 treatment	 and	 subsequently	 resumed	
     |  691FERENCI Et al.















































































































































Total GT1a† GT1b GT4
(C)
(D)

















































































these	 patients	 were	 cardiac	 failure	 (n	=	1),	 cardiopulmonary	 failure	
(n	=	1),	 myocardial	 infarction	 (n	=	1),	 gastrointestinal	 haemorrhage	
(n	=	1),	 oesophageal	 variceal	 haemorrhage	 (n	=	1),	 decompensated	
liver	cirrhosis	(n	=	1),	hepatic	failure	(n	=	1),	acute	pyonephrosis	(n	=	1;	
renal	 abscess),	 sepsis	 (n	=	1;	 thoracic	 wall	 abscess	 due	 to	 immuno-













The	 incidence	 of	 post-	baseline	 Grade	 3	 or	 higher	 laboratory	







respectively.	A	 summary	of	 laboratory	abnormalities	by	 treatment	
regimen	is	shown	in	Table	S5.
The	mean	(standard	deviation	[SD])	treatment	duration	of	OBV/





































Overall 55	(4) 90	(4) 13	(11) 35	(7) 35	(3) 37	(3) 7	(7) 18	(6)
On-	treatment	virologic	
failureb
13	(1) 26	(1) 3	(3) 9	(2) 7	(<1) 8	(<1) 3	(3) 9	(3)
Relapsec 11	(<1) 28	(1) 1	(<1) 14	(3) 9	(<1) 10	(<1) 1	(1) 4	(1)
Death 13	(1) 11	(<1) 2	(2) 3	(<1) 10	(1) 7	(<1) 1	(1) 1	(<1)
Premature	study	drug	
discontinuationd













     |  693FERENCI Et al.
4  | DISCUSSION
This	pooled	analysis	of	patient-	level	data	 from	post-	marketing	ob-
servational studies was conducted to evaluate the safety and ef-
fectiveness	 of	 OBV/PTV/r	±	DSV	±	RBV,	 including	 the	 impact	 of	
common comorbidities and comedications, when used in daily clini-
cal	practice	and	 in	 accordance	with	 local	 guidelines	and	 label	 rec-
ommendations.	The	results	provide	real-	world	evidence	that	these	
regimens	 are	 highly	 effective	 in	 patients	 infected	 with	 HCV	 GT1	







Overall,	 SVR	 rates	 remained	 high	 regardless	 of	 cirrhosis	 sta-
tus,	 prior	 HCV	 treatment	 experience	 or	 RBV	 coadministration.	




peginterferon-	based	 treatment,	 despite	 the	 recommended	 treat-
ment	duration	of	24	weeks.1–3	However,	in	clinical	trials,	lower	SVR12	








As	 expected,	 most	 patients	 had	 ≥1	 comorbidity	 and	 SVR12	
rates	 were	 numerically	 similar	 between	 patients	 with	 versus	



















DAA	 therapies	 interact	 with	 drug-	metabolizing	 enzymes	 or	 drug	




patients	 are	assessed	 for	 comorbidities	 and	potential	DDIs	before	
undergoing	 DAA	 treatment,	 and	 before	 starting	 other	 comedica-
tions	 during	DAA	 treatment.5,6	OBV/PTV/r	±	DSV-	based	 regimens	
are contraindicated for coadministration with drugs that are highly 
dependent	on	CYP3A	for	clearance,	strong	inducers	of	CYP3A	and	
CYP2C8,	and	strong	inhibitors	of	CYP2C8.1–4
Studies	 in	 large	 real-	world	 cohorts	 have	 shown	 that	 a	 signifi-
cant	number	of	patients	 receiving	comedications	and	treated	with	
OBV/PTV/r	±	DSV	±	RBV	 are	 potentially	 at	 risk	 for	 DDIs.17,29	 In	





OBV/PTV/r + RBV 
N = 455
OBV/PTV/r + DSV 
N = 1930


















At	least	1	AE 2	(100) 4	(22) 37	(32) 96	(28) 103	(24) 331	(22) 209	(27) 225	(34)
Serious	AEs 0 0 8	(7) 6	(2) 24	(6) 28	(2) 40	(5) 23	(3)
AEs	leading	to	
death
0 0 1	(<1) 0 2	(<1) 1	(<1) 6	(<1) 4	(<1)
Common	AEs	(in	≥5%	of	patients)a
 Anaemia 0 0 18	(16) 28	(8) 1	(<1) 2	(<1) 95	(12) 58	(9)
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≥1	 comedication	 during	 the	 treatment	 period.	 None	 of	 the	 most	
commonly used comedications were contraindicated, although 7 
had	clinically	relevant	DDIs.	Nevertheless,	>90%	of	patients	taking	
comedications continued to receive at least 1 of their drugs during 
treatment.	We	specifically	evaluated	the	treatment	profiles	of	drugs	
for	peptic	ulcers	and	GERD,	statins,	antiepileptics	and	antipsychot-
ics because these drug classes include several medications that are 


















not	 use	 these	 drugs	 before	 or	 during	 DAA	 treatment	 (90%-	92%	
vs	 96%).	 However,	 more	 than	 half	 of	 the	 patients	 taking	 statins	
required	 adjustments	 before	 or	 during	 OBV/PTV/r	±	DSV	±	RBV	
treatment.	These	adjustments	are	consistent	with	drug	labelling	for	
OBV/PTV/r	±	DSV,	which	stipulates	that	members	of	the	statin	class	




tic classes also include several drugs that are contraindicated with 
OBV/PTV/r	±	DSV.	The	antiepileptic	drugs	carbamazepine,	phenyt-
oin	and	phenobarbital	may	decrease	exposures	of	OBV,	PTV,	DSV	
and	ritonavir	 (via	CYP3A4	 induction),	 leading	 to	a	potential	 loss	 in	
anti-	HCV	therapeutic	activity	and	therefore	must	not	be	coadminis-
tered.1–4	Exposures	to	the	antipsychotic	drugs	lurasidone,	pimozide	
or	 quetiapine	 may	 be	 increased	 when	 coadministered	 with	 OBV/
PTV/r	±	DSV	(via	CYP3A4	inhibition	by	ritonavir),	potentially	leading	
to	serious	or	life-	threatening	adverse	reactions.1–4	Overall,	however,	
more	 than	 80%	 of	 patients	 continued	 to	 receive	 each	 drug	 class	
without change to their management.
The	 overall	 incidence	 of	 treatment-	emergent	 AEs	 (26%)	 was	
considerably	lower	than	that	seen	in	pivotal	clinical	trials	of	OBV/
PTV/r	±	DSV-	based	 regimens	 (67%-	92%),	 suggesting	 that	 safety	
outcomes	may	have	been	underreported	in	this	real-	world	study.	
The	 incidence	of	 serious	AEs	 (3%)	was	 consistent	with	 rates	 re-
ported	 in	clinical	 trials.7–12	No	new	or	unexpected	AEs	were	ob-
served,	and	fatigue	and	anaemia	were	the	only	AEs	that	occurred	
in	>5%	 of	 the	 overall	 population.	 As	 expected,	 the	 incidence	 of	
anaemia	was	more	frequent	 in	patients	who	received	RBV	in	the	
present	 study	 and	was	 the	main	 reason	 for	 patients	 discontinu-
ing	 RBV	 treatment	 before	 terminating	 OBV/PTV/r	±	DSV	+	RBV	
regimens.	 Low	 rates	 (3.1%)	 of	 DAA	 drug	 discontinuation	 were	
observed,	consistent	with	the	rates	in	clinical	trials.	Similarly,	the	
incidence of laboratory abnormalities was largely in accordance 
with that seen in clinical trials.7–12
The	number	of	large	real-	world	studies	of	OBV/PTV/r	±	DSV	±	RBV	
regimens	 in	 routine	 clinical	 practice	 is	 currently	 limited.	 Clinical	
	practice	data	from	the	German	Hepatitis	C	Registry,	which	included	
558	 patients	 treated	 with	 OBV/PTV/r	±	DSV	±	RBV,	 showed	 that	
SVR12	rates	were	96%	in	GT1-	and	100%	in	GT4-	infected	patients,	
regardless	of	 cirrhosis	 status	or	prior	 antiviral	 treatment.30	The	 in-
cidence	of	AEs	and	serious	AEs	were	52%	and	2%,	 respectively.	A	
meta-	analysis	of	real-	world	data	from	5726	patients	receiving	OBV/













Care	System	have	 reported	overall	 SVR12	 rates	 in	 the	 range	86%-	
95%	in	GT1-	infected	patients	treated	with	OBV/PTV/r	±	DSV-	based	
regimens,	which	 is	 approaching	 the	 rate	 seen	 in	 clinical	 trials.34–36 
Lower	SVR12	rates	in	this	US	Veteran	population	are	not	unexpected	
because	these	patients	tend	to	have	a	high	prevalence	of	comorbid-
ities	 that	have	historically	been	considered	difficult	 to	 treat.	Other	
real-	world	studies	of	OBV/PTV/r	±	DSV-	based	regimens	have	shown	
SVR12	rates	that	are	equivalent	to	the	rates	seen	in	clinical	trials.37–39 
Taken	 together,	our	 results	 support	 the	accumulating	body	of	 real-	
world	 evidence	 confirming	 the	 safety	 and	 effectiveness	 of	 OBV/
PTV/r	±	DSV	±	RBV	regimens	in	routine	clinical	practice.
This	analysis	has	several	limitations.	As	with	any	real-	world	study,	
there	 is	 scope	 for	 considerable	 bias	 in	 the	 reporting	 and	 collection	
of	patient-	level	 information.	In	particular,	safety	outcomes	are	often	
limited	 by	 underreporting	 in	 the	 real-	world	 setting.	 Additionally,	
DDI	screening	prior	to	the	initiation	of	antiviral	treatment	will	often	
predicate	 the	 choice	 of	 DAA	 drug	 based	 on	 comedication	 usage.	
Nevertheless,	we	observed	 comedication	 class	 usage	 typical	 of	 the	
comorbidities	seen	in	this	real-	world	cohort.	The	reasons	for	changes	
in	comedication	management	were	not	reported;	therefore,	it	was	not	
determined whether adjustments in comedications were as a result of 
DDIs.	A	further	limitation	was	that	information	regarding	comedica-
tion	dose	modification	or	temporary	interruption	was	not	documented	
in	 patients	who	were	 classified	 as	 having	 continuous	 comedication	
treatment.	It	was	also	not	possible	to	establish	a	relationship	between	
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DDIs	and	AEs.	Finally,	some	subgroups	in	this	analysis	had	compara-
tively	 small	patient	numbers,	and	 therefore,	meaningful	 conclusions	
on	safety	and	effectiveness	cannot	be	inferred	using	these	subgroups.
Although	 several	 new	 pangenotypic	 DAA	 regimens	 are	 now	
approved	 for	 the	 treatment	 of	 chronic	 HCV	 infection,	 access	 is	




patients	 provides	 evidence	 that	 in	 daily	 clinical	 practice,	 OBV/
PTV/r	±	DSV	±	RBV	 regimens	 are	 effective	 treatment	 options	 for	
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